George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Looks like £20k buy just went through at 11.75p...
Will be interesting to see what bid price is in first auction. C4s first auction appears to be in late June. If it follows that sort of pattern, there might even be some news on one of the current clinical trials by then...
About £700k left in the bank, so yes, it can't be too long before something is known on that front...
Good points Moniman. And actually quite an important next couple of months for Redx in terms of news flow on two separate clinical trials they have going at the moment.
It's possible they were trying to get SP much higher than now before doing a placing. who knows.
Could be. Will be interesting to see if more big buys are printed this afternoon. (I think action recently has been in late afternoon as Tang are based in California!)
Decent points Franky. But why do they keep talking about a raise in RNSs etc, but not actually announcing it???
One big reason they won't go private any time soon is because there's virtually no II shareholders in this of any significance. It's all about PIs, and GDR know there's no chance you lot would vote through delisting!
I think the word "partners" was used before. I took this to mean the firms that will actually sell AIHL across the US. Likely to be different firms involved in different regions. But no hurry to name names as they don't even have the data yet to make the actual FDA application. And to get the data they need funding to pay for the trials. Presumably they will now announce a proper fundraising. It would be very odd if they just went for another RF drawdown instead after just releasing this RNS. They'll need at least a couple of million just to get the trials done.
Might get interesting yet again though Moniman. If you look at trades just printed on here, some large ones just appeared again. So looks to me like Tang or another II is loading up again.
AJ Bell.
However, looking at JK Jenkins info. again appears my current broker (Bestinvest) actually are linked up to JK Jenkins. It was just when I rang them they didn't seem to know about it. Plus, they're listed on JK Jenkins under old brand name. lol.
Just been told I won't be able to use JP Jenkins facility if stock is transferred (in SIPP) after actual deilsting takes place (or they may mean they won't be able to accept the transfer). This is despite them having relationship with JP Jenkins.
Has anyone else been told something like this?
If big buying restarts then 20p certainly possible in short order. Otherwise would guess it's more likely going to be max 15-16p before deilsting. I think commission lower on AIM than if buying through the private auction facility so makes sense for anyone to load up now if looking to invest more in this.
Personally think if NHS want more lab capacity they will just add it (that might take some time though). Having more lab capacity available also theoretically makes country more resilient to any future pandemic as well.
Price unpredictable these last sessions, especially if more big buying emerges.
BTW, what do people think is the probability of success for the RXC007 Phase 2 trial that's meant to be concluding within the next two months or so?
It's getting a full recommendation for stroke product. But problem is that full recommendation for this is basically saying "only use when lab test not available". I think this stock is very unlikely to delist as not much for them to get from that as things stand right now.
I'd be far more convinced if a major health fund/II bought in again or helped directly with fundraising as long-term investor. Even CEO/CFO buying would lend a little confidence to this. Guess they'll probably announce another drawdown from RF at the beginning of next month to keep the lights on.
The recent big buyer was Tang. If they or someone like them start that again, price will rise. But at this precise moment, it feels like it's mainly trickle of sells going through by people who presumably can't/don't want to hold this anymore due to delisting.
Seems like Tang could easily afford to buy REDX outright. Even if they end up having to pay multiples of current SP for much of the shares.
Rayte's question explains why a lot of people sell in this situation (especially if smallish holding). Mine in a SIPP but also hassle as I'm having to get it transferred to a different provider so I have the option of trading it on the Jenkins platform (though wouldnt be surprised if more brokers sign up to Jenkins now). Also does anyone think some IIs will try to sell now because they have shares in a fund where the mandate is for holding listed companies (rather than private companies)? My guess is II like that with smallish holding will offload - would be surprised if Polar would sell all at these low prices as they have more to lose?
Roger, It's going to be a full recommendation for stroke product (not EVA like for AIHL). But you have to look at the wording of the guidance. It says "when lab testing not available". Who knows what actual demand will look like.